In preclinical diet-induced obesity models, Aardvark’s fixed-dose candidate ARD-201 reduced body weight by roughly 19% over 30 days, comparable to high-dose tirzepatide, and achieved about 30% weight loss when combined with low-dose tirzepatide. The regimen reduced fat mass while preserving lean mass and delivered glucose control on par with high-dose tirzepatide; co-administration with low-dose tirzepatide produced the fastest glucose clearance. Separately, a randomized Phase 2a study of ARD-101 in adults with obesity showed signals of weight control, reduced hunger, and metabolic improvements, with no serious adverse events or discontinuations reported.
The company used ObesityWeek 2025 to frame ARD-201—an oral fixed-dose combination of the TAS2R agonist ARD-101 and the DPP-4 inhibitor sitagliptin—as a bid to “own the off-ramp” from GLP-1 receptor agonists. Two Phase 2 studies are planned: POWER, expected to start by year-end 2025, will test the prevention of weight regain in participants who discontinue GLP-1 therapy after achieving roughly 15% weight loss; STRENGTH, targeted for the first half of 2026, will evaluate placebo-adjusted weight loss and the additive effect of GLP-1s. Aardvark also highlighted WE-868, an isoflavonoid modulator of oxidative metabolism that produced dose-dependent weight loss in preclinical studies and outperformed semaglutide at medium and high doses in DIO mice. ARD-101 remains in a separate Phase 3 program for hyperphagia in Prader–Willi syndrome.
Strategically, the company is positioning around two pressure points in the incretin era: discontinuation and body composition. With real-world GLP-1 drop-off driving rebound weight gain, a maintenance or bridging therapy that preserves lean mass and stabilizes glycemic control could be attractive to both clinicians and payers if efficacy and tolerability translate to humans. Anchoring ARD-201 to sitagliptin may de-risk safety and enable a 505(b)(2)-style path, while the TAS2R mechanism provides a distinct gut–brain axis angle that could sidestep some GI liabilities associated with higher-dose GLP-1 regimens. The preclinical synergy with low-dose incretins hints at a dose-sparing strategy that could matter in cost-constrained or supply-limited environments.
For sites and CROs, the POWER protocol will hinge on clean documentation of prior GLP-1 exposure and quantification of approximately 15% antecedent weight loss, creating operational dependence on EHR reconciliation, pharmacy data, and consistent run-in criteria. The maintenance claim will likely require body composition endpoints to substantiate lean-mass preservation, increasing the need for DXA capacity and standardized imaging workflows. STRENGTH, if designed to satisfy the FDA’s combination rule, may require factorial elements to demonstrate each component’s contribution—adding complexity to randomization schemas and sample sizing. Vendors supporting remote weight capture and metabolic monitoring could see demand if the trials lean into decentralized assessments to broaden recruitment.
The next signal to watch is how Aardvark defines endpoints, duration, and discontinuation windows in POWER, and whether STRENGTH incorporates a factorial design to de-risk regulatory pathfinding. Translation is the central risk: lean-mass preservation and glycemic benefits seen in mice must replicate in humans, and DPP-4 inhibitors have historically been weight-neutral, raising the bar for demonstrating placebo-adjusted weight loss and meaningful maintenance after GLP-1 cessation. Read-through from the ARD-101 PWS program could help with safety and GI tolerability, but the obesity population presents a different profile. Manufacturing a fixed-dose combination with a generic component also introduces formulation and scale-up dependencies. If the Phase 2 package shows credible maintenance and additive effects with acceptable tolerability, expect payer interest in step-down algorithms and pressure on incretin dosing strategies; if not, ARD-201 risks being another adjunct in an increasingly crowded obesity toolkit.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Caliway’s CBL-514 Phase 2 Combination Trial Cleared; Phase 3 SUPREME-01 Enrolling
3 weeks ago[…] sharp. The trial targets a specific vulnerability in GLP-1 therapy: fat cells shrink on tirzepatide but are not eliminated, so weight regain after discontinuation is a documented clinical problem. […]
Comments are closed.